乐观
$7.05
情景价格
$2.170
+0.020 (+0.93%)收盘时
Callan JMB Inc. is a vertically integrated logistics and fulfillment company, which provides thermal management logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. The Company provides comprehensive alternatives to all logistics solutions and services utilized for frozen shipping in the life sciences industry (personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). Its Ship2Q ultraviolet disinfection process (Safe Hygienic Irradiation Performance Process & Qualification) ensures fitness, thermal reliability, and cleanliness of the system components within the manufacturers specifications equal to new off-the-shelf shipper systems.
Callan JMB Inc. is currently not a good buy due to its ongoing financial struggles, as evidenced by a net income loss of $3,215,054 in Q1 2026 and a year-to-date change of +103.57%, which is overshadowed by a one-year change of -46.23%.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Callan JMB Acquires Reger Oil Energy Assets to Enhance Domestic Development

Callan JMB and ASU Partner to Establish Electrical Equipment Manufacturing Facility

Strategic Partnership Accelerates Pharmaceutical Onshoring

Callan JMB Expands Public Infrastructure Contract

CALLAN JMB INC AIMS TO SEEK FOREIGN-TRADE ZONE SUBZONE STATUS FOR ATLAS COMPLEX
Callan JMB Inc. is a vertically integrated logistics and fulfillment company, which provides thermal management logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. The Company provides comprehensive alternatives to all logistics solutions and services utilized for frozen shipping in the life sciences industry (personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). Its Ship2Q ultraviolet disinfection process (Safe Hygienic Irradiation Performance Process & Qualification) ensures fitness, thermal reliability, and cleanliness of the system components within the manufacturers specifications equal to new off-the-shelf shipper systems. It operates in the Industrials sector.
Callan JMB Inc. is currently not a good buy due to its ongoing financial struggles, as evidenced by a net income loss of $3,215,054 in Q1 2026 and a year-to-date change of +103.57%, which is overshadowed by a one-year change of -46.23%.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。